-
1.发明申请公开(公告)号：US20110124708A1
公开(公告)日：2011-05-26
申请号：US12967121
申请日：2010-12-14
IPC分类号： A61K31/713 , A61P27/02 , A61P9/12
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; 1和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
公开(公告)号：US20090326044A1
公开(公告)日：2009-12-31
申请号：US12536698
申请日：2009-08-06
IPC分类号： A61K31/7105
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K—2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
3.发明申请RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONS 审中-公开RNAi介导的抑制肿瘤坏死因子ALPHA相关病症公开(公告)号：US20100166676A1
公开(公告)日：2010-07-01
申请号：US12700188
申请日：2010-02-04
IPC分类号： A61K9/12 , A61K31/7088 , A61K31/7125
CPC分类号： C12N15/1138 , A61K31/7088 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/346 , C12N2310/351 , C12N2320/30
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma, for example.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这样的TNFα靶标可用于治疗患有TNFα相关病症或具有发展TNFα相关病症如眼病干眼症，过敏性结膜炎或眼部炎症或诸如皮炎，鼻炎的患者的患者 ，或哮喘。
-
公开(公告)号：US07592324B2
公开(公告)日：2009-09-22
申请号：US11345361
申请日：2006-02-01
CPC分类号： C12N15/1137 , C12N15/1138 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y301/01007 , C12Y306/03009 , C12Y402/01001
摘要： RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
摘要翻译： 提供RNA干扰用于抑制眼高血压靶mRNA表达，以降低开角型青光眼或高眼压患者的眼内压升高。 眼睛高血压指标包括碳酸酐酶II，IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + / K + -ATPase; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。
-
5.发明授权RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions 有权连接蛋白43的RNAi介导的抑制用于治疗IOP相关病症公开(公告)号：US09173896B2
公开(公告)日：2015-11-03
申请号：US12371007
申请日：2009-02-13
申请人： Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
发明人： Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
IPC分类号： A61K31/713 , C12N15/113
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
摘要翻译： 提供RNA干扰抑制连接蛋白43（Cx43）在眼内压相关条件下，包括眼高压和青光眼如正常眼压青光眼和开角型青光眼。
-
6.发明授权RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma 有权RNAi相关抑制TNFα信号通路治疗青光眼公开(公告)号：US08865670B2
公开(公告)日：2014-10-21
申请号：US13024621
申请日：2011-02-10
CPC分类号： C12N15/1138 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是沉默这种TNFα靶标可用于治疗患有TNFα相关病症的患者或具有发展TNFα相关病症的风险，例如与眼内压升高（IOP）相关的眼部病症，包括青光眼和高眼压症。
-
7.发明申请RNAI-MEDIATED INHIBITION OF FRIZZLED RELATED PROTEIN-1 FOR TREATMENT OF GLAUCOMA 有权用于治疗葡萄球菌的相关蛋白-1的RNAi介导的抑制公开(公告)号：US20120178795A1
公开(公告)日：2012-07-12
申请号：US13429913
申请日：2012-03-26
IPC分类号： A61K31/713 , A61P27/06
CPC分类号： C12N15/113 , A61K9/0048 , A61K31/7088 , A61K31/713 , A61K38/00 , A61K48/00 , C12N2310/111 , C12N2310/14 , C12N2310/316 , C12N2310/321 , C12N2310/351
摘要： RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
摘要翻译： 提供RNA干扰用于抑制卷曲相关蛋白-1 mRNA表达，特别是用于治疗患有青光眼或有发展青光眼风险的患者。
-
8.发明申请RNAi-MEDIATED INHIBITION OF CONNEXIN 43 FOR TREATMENT OF IOP-RELATED CONDITIONS 有权用于治疗眼压相关病症的连接蛋白43的RNAi介导的抑制公开(公告)号：US20090209627A1
公开(公告)日：2009-08-20
申请号：US12371007
申请日：2009-02-13
申请人： Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
发明人： Jon E. Chatterton , Abbot F. Clark , Martin B. Wax
IPC分类号： A61K31/7105 , C07H21/02 , A61P27/02 , A61K48/00
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30
摘要： RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
摘要翻译： 提供RNA干扰抑制连接蛋白43（Cx43）在眼内压相关条件下，包括眼高压和青光眼如正常眼压青光眼和开角型青光眼。
-
9.发明申请RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA 审中-公开用于治疗乳腺癌的TNFα信号通路的RNAi相关性抑制公开(公告)号：US20090036397A1
公开(公告)日：2009-02-05
申请号：US12185182
申请日：2008-08-04
IPC分类号： A61K31/713 , A61P27/02
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular edema.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFalpha）。 特别是沉默这种TNFα靶标对于治疗患有或有发生黄斑水肿危险的患者是有用的。
-
10.发明授权RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis 有权RNAi相关抑制TNFα信号通路治疗眼血管生成公开(公告)号：US08754202B2
公开(公告)日：2014-06-17
申请号：US13169549
申请日：2011-06-27
IPC分类号： C07H21/04
CPC分类号： C12N15/1138 , C12N15/113 , C12N15/1136 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12N2310/31 , C12N2310/319 , C12N2310/32 , C12N2310/321 , C12N2310/53 , C12N2310/531
摘要： RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition, such as ocular angiogenesis, retinal ischemia, and diabetic retinopathy.
摘要翻译： 通过沉默TNFα细胞表面受体TNF受体-1（TNFR1）mRNA表达或沉默TNFα转化酶（TACE / ADAM17）mRNA表达，提供RNA干扰抑制肿瘤坏死因子α（TNFα）。 特别是使TNFα靶标沉默可用于治疗患有TNFα相关病症或出现TNFα相关病症如眼血管生成，视网膜缺血和糖尿病性视网膜病变的风险的患者。
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.029 秒)
